

SUMMARY

This shall constitute a summary of the Final Terms (the "**Summary**") pursuant to article 56 para. 2 of the Swiss Federal Ordinance on Financial Services ("**FinSO**") and an introduction to the Final Terms. Any investment decision regarding the Product must not only be based on the information provided in this Summary. The Issuer may only be held liable for the content of this Summary if it is misleading, inaccurate or inconsistent when read together with the other parts of the Final Terms and the Issuance and Offering Programme.

The Product documented in the respective Final Terms may be considered a structured product in Switzerland pursuant to article 70 of the Swiss Federal Act on Financial Services ("**FinSA**") and is neither subject to authorisation nor supervision by the Swiss Financial Market Supervisory Authority ("**FINMA**"). Investors bear the credit risk of the Issuer. Investors should read the section "Risk Factors" of the Issuance and Offering Programme and, if applicable, the section "Additional Risk Factors" of the Final Terms.

Investing in this Product may put Investor's capital at risk. Investors may lose some or all of their investment.

The Product may only be offered, sold or advertised, directly or indirectly, in Switzerland in accordance with the requirements of the FinSA, as further set out in the Issuance and Offering Programme and the Final Terms. Terms used in this Summary shall have the same meaning as set forth in the Issuance and Offering Programme and the Final Terms.

Information on the Product

Product name	20.39% p.a. Multi Barrier Reverse Convertible on Moderna, Novartis, Roche	SSPA Product Type	1230 (as defined in the SSPA Swiss Derivative Map)
ISIN	CH1481480114	Swiss Security Number	148148011
SIX Symbol	ADWYSQ	Issuer	Swissquote Bank SA, Gland, Switzerland
Issuer Rating	n/a	Supervisory Authority of the Issuer	FINMA
Issue Size	CHF 10'000'000 (can be increased at any time)	Settlement Currency	CHF
Denomination	CHF 1'000	Issue Date	07/07/2026
Redemption Date	07/07/2027	Initial Fixing Date	29/06/2026 (or the day when the Subscription Period ends)
Final Fixing Date	29/06/2027	Underlying	Moderna, Novartis, Roche
Depository	SIX SIS Ltd	Settlement Type(s)	Cash Settlement or Delivery of Underlying

Information on the Offering and Admission to Trading

Issue Price	100.00% of the Denomination
Subscription Period	22/06/2026 - 29/06/2026
Listing / Exchange	SIX Swiss Exchange AG; traded on SIX Swiss Exchange - Structured Products
First Exchange Trading Date	07/07/2026 (anticipated)
Clearing	SIX SIS Ltd, Euroclear, Clearstream
Selling Restrictions	As specified in the respective Issuance and Offering Programme and respective Final Terms.



Swissquote Bank SA
(the "Issuer")

INDICATIVE FINAL TERMS

dated
22 June 2026

**20.39% p.a. Multi Barrier Reverse Convertible on Moderna, Novartis, Roche
under the Issuance and Offering Programme dated 24 September 2025 (the "Programme" or the "Base Prospectus")**

(the "Products")

ISIN CH1481480114
Swiss Security Number 148148011
SIX Symbol ADWYSQ

These indicative Final Terms (the "**Final Terms**") are supplemental to and should be read in conjunction with the Base Prospectus dated 24 September 2025, which expires on 23 September 2026, or, in case such Base Prospectus is replaced by another Base Prospectus by the Issue Date, in conjunction with the latest valid version of the Base Prospectus that has been published by the Issue Date (such most recently published Base Prospectus, as amended from time to time, the "**Base Prospectus**").

The information in these indicative Final Terms is not complete and is subject to completion and amendments which may be made until the Initial Fixing Date (as defined below). These indicative Final Terms constitute indicative final terms within the meaning of article 45 para. 3 of the Swiss Federal Act on Financial Services ("**FinSA**") and will not be registered with SIX Exchange Regulation in its capacity as Swiss Prospectus Office in accordance with FinSA. These indicative Final Terms may be used for the purpose of a public offering directly or indirectly, in Switzerland to retail clients (Privatkundinnen und -kunden) within the meaning of FinSA ("**Retail Clients**") in accordance with FinSA during the Subscription Period. The Products are not FinSA Exempt Products.

There is no obligation of the Issuer and/or the Lead Manager or any third party to list the Product or apply for admission to trading at issuance or during the term of the Product. In case of a Product that is listed or admitted to trading, there is no obligation to maintain a listing/admission to trading during the term of the Product.

The Products documented in these indicative Final Terms qualify as debt instruments with a derivative character (*Forderungspapiere mit derivativem Charakter*) according to Swiss law and may be considered structured products in Switzerland pursuant to article 70 FinSA and are neither subject to authorisation nor supervision by the Swiss Financial Market Supervisory Authority ("**FINMA**"). None of the Products constitute a participation in a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes ("**CISA**") and investors do not benefit from the specific investor protection provided under CISA. Investors bear the credit risk of the Issuer and the Guarantor, if any. **Investors should read the section "Risk Factors" of the Base Prospectus and, if applicable, the section "Additional Information and Risk Factors" of these indicative Final Terms. Investing in this product may put Investor's capital at risk. Investor may lose some or all of its investment.**

Terms used herein shall have the same meaning as set forth in the Base Prospectus. Full information on the Issuer, the Guarantor, if any, and the offer and structure of the Products can only be assessed on the basis of the combination of these indicative Final Terms and the Base Prospectus.

In case of inconsistencies between the provisions of the Base Prospectus and the indicative Final Terms, or provisions introduced by the indicative Final Terms, the indicative Final Terms shall prevail.

On or prior to the date of expiration of the Base Prospectus, a new base prospectus (the "**New Base Prospectus**") will be published on the Notification Website. Following the expiry of the Base Prospectus the offering of the Products will continue under the New Base Prospectus. The terms and conditions from the Base Prospectus will be incorporated by reference into the New Base Prospectus and will continue to apply to the Products.

A. Product details and operational information

Product name	20.39% p.a. Multi Barrier Reverse Convertible on Moderna, Novartis, Roche
ISIN	CH1481480114
Swiss Security Number	148148011
SIX Symbol	ADWYSQ
SSPA Product Type	1230 (as defined in the SSPA Swiss Derivative Map)
Capital Protection	Not applicable
Issuer	Swissquote Bank SA, Gland, Switzerland (Rating: n/a, Supervisory Authority: FINMA)
Lead Manager	Leonteq Securities AG, Zurich, Switzerland
Calculation Agent	Leonteq Securities AG, Zurich, Switzerland
Paying Agent	Leonteq Securities AG, Zurich, Switzerland
Guarantee	Not applicable

B. Product and contractual terms

General

Issue Price	100.00% of the Denomination
Issue Size	CHF 10'000'000 (can be increased at any time)
Denomination	CHF 1'000
Settlement Currency	CHF
Currency Protection	Quanto CHF
Product Type	Fixed-end Product

Dates

Subscription Start Date	22/06/2026
Subscription End Date	29/06/2026 14:00 CEST (please note that the Subscription Period might be closed earlier)
Subscription Period	The period starting on the Subscription Start Date and ending on the Subscription End Date.
Initial Fixing Date	29/06/2026 (or the day when the Subscription Period ends)
Issue Date	07/07/2026
First Exchange Trading Date	07/07/2026 (anticipated)
Last Trading Day/Time	29/06/2027 / Exchange market close
Final Fixing Date	29/06/2027 (subject to Market Disruption Event provisions)
Redemption Date	07/07/2027 (subject to Settlement Disruption Event provisions)

Underlying

Underlying(s) The Underlying is or is composed of the following components: Share, Participation Certificate

Underlying	Related Exchange	Bloomberg Ticker	Initial Fixing Level (100%)*	Barrier Level (52.50%)*	Strike Level (100.00%)*	Conversion Ratio
MODERNA INC US60770K1079	NASDAQ	MRNA UQ	USD TBA	USD TBA	USD TBA	TBA**
NOVARTIS AG-REG CH0012005267	SIX Swiss Exchange AG	NOVN SW	CHF TBA	CHF TBA	CHF TBA	TBA*
ROCHE HOLDING AG-PARTIZIPATIONSSCHEIN CH1499059983	SIX Swiss Exchange AG	ROP SW	CHF TBA	CHF TBA	CHF TBA	TBA*

* will be determined on the Initial Fixing Date (levels are expressed in percentage of the Initial Fixing Level)

** will be determined on the Final Fixing Date

Underlying Valuation Dates Adjustments for Disrupted Dates	Individual Adjustment
Maximum Days of Disruption	8

Coupon

Coupon Rate	20.39% p.a.
Coupon Amount(s) and Coupon Payment Date(s)	In case no Early Redemption has occurred, the following applies: The Coupon Amount(s) per Product will be paid in the Settlement Currency

on the respective Coupon Payment Date(s). Following Business Day Convention applies.

CHF 50.98 paid on 06/10/2026
 CHF 50.98 paid on 06/01/2027
 CHF 50.98 paid on 06/04/2027
 CHF 50.98 paid on 07/07/2027

Day Count Fraction

30/360, Unadjusted, Accruing during each coupon period (including start and excluding end date)

Early Redemption

Early Redemption Observation and Early Redemption Dates

	Early Redemption Observation Date	Early Redemption Date
1	29/09/2026	06/10/2026
2	29/12/2026	06/01/2027
3	30/03/2027	06/04/2027

Early Redemption

On each Early Redemption Observation Date, the Issuer has the right, but not the obligation to call all Products for Early Redemption on the respective Early Redemption Date.

On the respective Early Redemption Date the Investor will receive a Cash Settlement in the Settlement Currency equal to the Denomination, plus the Coupon Amount for the respective Coupon Payment Date. No further payments will be made thereafter.

Redemption

Settlement Type(s) Redemption Scenario

Cash Settlement or Delivery of Underlying
 Provided that no Early Redemption occurred, the Investor is entitled to receive from the Issuer on the Redemption Date:

- 1) If a Barrier Event has NOT occurred, the Investor will receive a Cash Settlement in the Settlement Currency equal to:
Denomination
- 2) If a Barrier Event has occurred, the Investor will receive a round number (i.e. Conversion Ratio) of the Underlying with the Worst Performance per Product. Any potential fractional Conversion Ratio entitlements (Fraction of Underlyings) will be paid in cash, based on the Final Fixing Level. Fractions of Underlyings will not be cumulated.

Initial Fixing Level

Official close of the respective Underlying on the Initial Fixing Date on the Related Exchange, as determined by the Calculation Agent.

Final Fixing Level

Official close of the respective Underlying on the Final Fixing Date on the Related Exchange, as determined by the Calculation Agent.

Worst Performance

For each Underlying the performance is calculated by dividing its Final Fixing Level by the respective Initial Fixing Level. The Worst Performance corresponds to the lowest of all so calculated values, as determined by the Calculation Agent.

Barrier Event

A Barrier Event shall be deemed to occur if at least one of the Underlyings' Final Fixing Levels is at or below the respective Barrier Level, as reasonably determined by the Calculation Agent.

Conversion Ratio

Denomination divided by the Strike Level which is expressed as absolute value in the relevant Underlying currency and converted where necessary into the Settlement Currency using the FX Rate.

FX Rate

The foreign exchange rate to be used for the conversion of the relevant Underlying currency into the Settlement Currency which appears on the Bloomberg page "BFIX" on the Final Fixing Date at 10 a.m. local time New York, respectively for Underlyings with the Related Exchange located in the Asia-Pacific region at 4 p.m. local time Hong Kong and as reasonably determined by the Calculation Agent.

C. Other information and terms

Distribution Fees	No Distribution Fees. The level of the Distribution Fee will be fixed on the Initial Fixing Date and might be higher or lower than the level indicated herein.
Listing / Exchange Secondary Market	SIX Swiss Exchange AG; traded on SIX Swiss Exchange - Structured Products Daily price indications will be available from 09:15 - 17:15 CET on www.swissquote.com , Refinitiv [SIX Symbol]=LEOZ or [ISIN]=LEOZ and Bloomberg [ISIN] Corp or on LEOZ.
Quoting Type	Secondary market prices are quoted dirty; accrued interest is included in the prices.
Quotation Type	Secondary market prices are quoted in percentage.
Minimum Investment	CHF 1'000
Minimum Trading Lot	CHF 1'000
Clearing	SIX SIS Ltd, Euroclear, Clearstream
Depository	SIX SIS Ltd
Public Offering Form	Switzerland Uncertificated Securities
Governing Law / Jurisdiction	Swiss / Gland
Notification Website	www.swissquote.com
Selling Restrictions	CH, UK, EEA, US, SG, HK (see Base Prospectus for more information)
Significant Changes	Except as disclosed in these Final Terms and the Base Prospectus, there has been no significant change in the financial or trading position of the Issuer and no material adverse change in the prospects of the Issuer and, if applicable the Guarantor since the last annual or, as the case may be, semi-annual report. The Issuer accepts responsibility for the information contained in these Final Terms. The Issuer declares that the information contained in these Final Terms is, to the best of its knowledge, in accordance with the facts and contains no omission of material information.